E Penz1, J Boffa2, D J Roberts3, D Fisher4, R Cooper5, P E Ronksley6, M T James7. 1. <sup>*</sup>Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan. 2. <sup>†</sup>Department of Community Health Sciences, University of Calgary, Calgary. 3. <sup>‡</sup>Departments of Surgery and Community Health Sciences, Intensive Care Unit Administration, Foothills Medical Centre, Calgary. 4. <sup>§</sup>Peter Lougheed Hospital, University of Calgary, Calgary. 5. <sup>¶</sup>Royal Alexandra Hospital, Edmonton, Alberta. 6. <sup>#</sup>Department of Clinical Epidemiology, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario. 7. <sup>**</sup>Departments of Medicine and Community Health Sciences, University of Calgary and the Foothills Medical Centre, Calgary, Alberta, Canada.
Abstract
BACKGROUND: Xpert(®) MTB/RIF is a commercially available nucleic acid amplification test developed for the diagnosis of pulmonary tuberculosis (PTB). OBJECTIVE: To determine the diagnostic accuracy of Xpert for the detection of extra-pulmonary tuberculosis (EPTB). METHODS: We searched MEDLINE, EMBASE and Global Health databases from January 2010 to 15 August 2014 for studies of diagnostic performance in which Xpert was examined against culture for patients with clinically suspected EPTB. Bivariate random effects models were used to provide pooled estimates of diagnostic accuracy. RESULTS: Thirty-six studies were identified, with a pooled sensitivity and specificity of respectively 77% (95%CI 66-85) and 97% (95%CI 94-98). Substantial variations existed between study estimates of sensitivity (I(2) = 99%) and specificity (I(2) = 96%). Among site-specific estimates for lymph, pleural fluid, cerebrospinal fluid, gastro-intestinal and urinary samples, the pooled sensitivity was lower in pleural fluid (37%, 95%CI 26-50, meta-regression P < 0.001) and higher in lymph node samples (87%, 95%CI 75-95, meta-regression P = 0.03). CONCLUSION: Xpert has high specificity but limited sensitivity for the detection of EPTB. Although positive Xpert test results may be useful in rapidly identifying EPTB cases, negative test results provide less certainty for ruling out disease.
BACKGROUND: Xpert(®) MTB/RIF is a commercially available nucleic acid amplification test developed for the diagnosis of pulmonary tuberculosis (PTB). OBJECTIVE: To determine the diagnostic accuracy of Xpert for the detection of extra-pulmonary tuberculosis (EPTB). METHODS: We searched MEDLINE, EMBASE and Global Health databases from January 2010 to 15 August 2014 for studies of diagnostic performance in which Xpert was examined against culture for patients with clinically suspected EPTB. Bivariate random effects models were used to provide pooled estimates of diagnostic accuracy. RESULTS: Thirty-six studies were identified, with a pooled sensitivity and specificity of respectively 77% (95%CI 66-85) and 97% (95%CI 94-98). Substantial variations existed between study estimates of sensitivity (I(2) = 99%) and specificity (I(2) = 96%). Among site-specific estimates for lymph, pleural fluid, cerebrospinal fluid, gastro-intestinal and urinary samples, the pooled sensitivity was lower in pleural fluid (37%, 95%CI 26-50, meta-regression P < 0.001) and higher in lymph node samples (87%, 95%CI 75-95, meta-regression P = 0.03). CONCLUSION: Xpert has high specificity but limited sensitivity for the detection of EPTB. Although positive Xpert test results may be useful in rapidly identifying EPTB cases, negative test results provide less certainty for ruling out disease.
Authors: Daniel Perez-Risco; David Rodriguez-Temporal; Ivan Valledor-Sanchez; Fernando Alcaide Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Adrian V Hernandez; Laryssa de Laurentis; Isadora Souza; Marcelo Pessanha; Priyaleela Thota; Yuani M Roman; Joshuan Barboza-Meca; David R Boulware; Jose E Vidal Journal: Trop Med Int Health Date: 2020-11-30 Impact factor: 2.622
Authors: A Andama; D Jaganath; R Crowder; L Asege; M Nakaye; D Katumba; S Mwebe; F Semitala; W Worodria; M Joloba; S Mohanty; A Somoskovi; A Cattamanchi Journal: Diagn Microbiol Infect Dis Date: 2019-09-04 Impact factor: 2.803
Authors: Lesley Scott; Pedro da Silva; Catharina C Boehme; Wendy Stevens; Christopher M Gilpin Journal: Curr Opin HIV AIDS Date: 2017-03 Impact factor: 4.283
Authors: Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2018-08-27
Authors: N C Bahr; L Tugume; R Rajasingham; R Kiggundu; D A Williams; B Morawski; D Alland; D B Meya; J Rhein; D R Boulware Journal: Int J Tuberc Lung Dis Date: 2015-10 Impact factor: 2.373
Authors: Sarman Singh; Bindu Dey; K S Sachdeva; S K Kabra; K K Chopra; Vijay K Chaudhary; Pawan Sharma; V M Katoch Journal: J Lab Physicians Date: 2015 Jan-Jun